Bifepramide, (+)- belong to the class of parasympatholytic agents that reduce the activity of the parasympathetic nervous system.

PF-00446687 is the highly selective, brain-penetrant, melanocortin 4 receptor (MC4R) agonist. PF-00446687 induced partner preferences formation in females prairie voles after a 6-h cohabitation without mating. PF-00446687 had been in phase I clinical trial for the treatment of sexual function disorders.

Levophencynonate is the active enantiomer of phencynonate. Levophencynonate is an anticholinergic agent which can prevent acute motion sickness with an efficacy similar to scopolamine. It will take effect by competitive binding to central muscarinic acetylcholine receptors. In April 2017 levophencynonate was in preregistration phase for the vertigo treatment in China.

Broxaterol is a β2 adrenoreceptor agonist used for the treatment of respiratory disease. Broxaterol produced a significant clinical improvement, an increase in FEV1 and a decrease in supplemental anti-asthmatic drugs used in patients with reversible airflow obstruction and in asthmatic children. The increases in FEV1 versus baseline were significantly maintained after the end of the treatment. Prompt disappearance of the asthmatic attack with significant improvement in lung function was observed in children. In two long-term controlled trials, the respiratory effects of broxaterol nebulizer solution were significantly greater than placebo. Moreover, broxaterol by metered dose inhaler was more effective than salbutamol after 3 months follow-up, showing the absence of tachyphylaxis. In long-term clinical evaluation, broxaterol has been shown to be well tolerated, with an incidence of adverse reactions equal to or less than that reported in the literature for other beta 2-agonists. The side effects most frequently associated with broxaterol were tremor, nervousness, and palpitations.